文献速递泌尿生殖与妇科肿瘤放疗

高剂量率近距离放疗单药治疗与低剂量率近距离放疗联合或不联合外照射放疗治疗临床局限性前列腺癌的比较

High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
PubMed 文献 · Radiother Oncol · 2018-11-08

本研究比较了352例接受高剂量率近距离放疗(HDR-BT)单药治疗与486例接受低剂量率近距离放疗(LDR-BT)联合或不联合外照射放疗(EBRT)的局限性前列腺癌患者。经IPTW校正后,两组5年生化无失败生存率(bNED)无显著差异;LDR-BT组急性≥2级泌尿生殖(GU)毒性发生率更高,但晚期≥2级GU和胃肠道(GI)毒性两组相当。

要点

  • HDR-BT单药与LDR-BT联合或不联合EBRT在低、中及选择的高危患者中bNED无显著差异。
  • LDR-BT组急性≥2级GU毒性发生率高于HDR-BT组,晚期1级GU毒性也更高。
  • 两组晚期≥2级GU和GI毒性累积发生率相当,均未观察到4级或5级毒性。

核心结论

  • HDR-BT单药治疗在低危、中危和选择的高危患者中显示出与LDR-BT联合或不联合EBRT相当的治疗结局。
  • LDR-BT与HDR-BT单药相比,晚期≥2级GI和GU毒性发生率相当,但急性≥2级GU毒性更高。

研究设计与样本

  • 比较352例接受HDR-BT单药治疗(中位随访84个月,NCCN风险分类低:中:高=28:145:179)和486例接受LDR-BT联合或不联合EBRT(随访90个月,194:254:38)的局限性前列腺癌患者。
  • 采用倾向性评分逆概率治疗加权(IPTW)以减少背景选择偏倚。

主要发现

  • 5年生化无失败生存率(bNED)在HDR-BT组和LDR-BT组分别为92.9%和95.6%(p=0.25)。
  • 低危组bNED在HDR-BT和LDR-BT分别为100%和97.3%(p=0.99),中危组分别为95.6%和94.3%(p=0.19),高危组分别为89.6%和94.9%(p=0.26),选择的高危组(排除T3b-4和初始PSA≥50)分别为93.1%和94.9%(p=0.98)。
  • IPTW校正后LDR-BT组与HDR-BT组bNED仍无差异。
  • LDR-BT组急性≥2级GU毒性发生率高于HDR-BT组,晚期1级GU毒性也更高。
  • 急性≥1级GU毒性可预测晚期≥2级GU毒性;EBRT联合LDR-BT较单纯LDR-BT增加GI毒性。

关键数值与推荐

  • HDR-BT组中位随访84个月,NCCN风险分类低:中:高=28:145:179;LDR-BT组随访90个月,低:中:高=194:254:38。
  • LDR-BT排除T3b-T4肿瘤和初始PSA>50 ng/ml的患者。
  • 两组均未检测到4级或5级毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare the outcome of high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and low-dose-rate brachytherapy (LDR-BT) with or without external beam radiotherapy (EBRT) for localized prostate cancer. METHODS AND MATERIALS: We compared 352 patients treated with HDR-BT as monotherapy (median follow-up time 84 months, NCCN risk classification; low: intermediate: high = 28:145:179) and 486 patients with LDR-BT with or without EBRT (90 months, 194:254:38). HDR-BT treated advanced disease with more hormonal therapy than LDR-BT. LDR-BT excluded patients with T3b-T4 tumor and initial PSA >50 ng/ml. Inverse probability of treatment weighting (IPTW) involving propensity scores was used to reduce background selection bias. RESULTS: The actuarial 5-year biochemical failure-free survival rates (bNED) were 92.9% and 95.6% (p = 0.25) in the HDR-BT and LDR-BT groups, respectively, and it was 100% and 97.3% (p = 0.99) in the low-risk, 95.6% and 94.3% (p = 0.19) in the intermediate, 89.6% and 94.9% (p = 0.26) in the high-risk groups, and 93.1% and 94.9% (p = 0.98) in selected high-risk group excluding T3b-4 and initial PSA ≥50. IPTW correction also indicated no difference in bNED between LDR-BT and HDR-BT groups. LDR-BT showed a higher incidence of genitourinary (GU) toxicity grade ≥2 than that of HDR-BT in the acute phase and grade 1 toxicity in late phase. Acute GU toxicity grade ≥1 predicted late GU toxicity grade ≥2. External beam radiotherapy plus LDR-BT elevated GI toxicity than LDR-BT only group. Accumulated incidence of late grade ≥2 GU and GU toxicity was equivalent between HDR-BT and LDR-BT. No grade 4 or 5 toxicities were detected in either modality. CONCLUSION: HDR-BT monotherapy showed an equivalent outcome to that of LDR-BT with or without EBRT for low-, intermediate- and selected high-risk patients. LDR-BT showed equivalent incidence of grade ≥2 late GI and GU toxicities and higher grade ≥2 acute GU toxicity as that of HDR-BT as a monotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yamazaki H, Masui K, Suzuki G, et al. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Radiother Oncol. 2018. PMID: 30416045. doi:10.1016/j.radonc.2018.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。